Electrophysiological Abnormalities in Type 2 Diabetic Patients with Reduced Levels of Insulin-like Growth Factor I

By Gódínez-Gómez R   Trujillo-Hernández B   Tene CE   Huerta M   Trujillo X   Vásquez C  

The Journal of International Medical Research, Vol. 34, Iss. 1, 2006-01 ,pp. : 21-29

Field House Publishing

Access to resources Recommend Favorite

Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

By Derosa Giuseppe   Maffioli Pamela   Salvadeo Sibilla AT   Ferrari Ilaria   Gravina Alessia   Mereu Roberto   D'Angelo Angela   Fogari Elena   Palumbo Ilaria   Randazzo Sabrina   Cicero Arrigo FG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 12, 2010-08 ,pp. : 1971-1982

Informa Healthcare

Access to resources Recommend Favorite

Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

By Ragia Georgia   Petridis Ioannis   Tavridou Anna   Christakidis Dimitrios   Manolopoulos Vangelis G  

Pharmacogenomics, Vol. 10, Iss. 11, 2009-11 ,pp. : 1781-1787

Future Medicine

Access to resources Recommend Favorite

Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients

By Malaisse Willy J  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2691-2698

Informa Healthcare

Access to resources Recommend Favorite

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

By Fujii Yuki   Abe Masanori   Higuchi Terumi   Mizuno Mari   Suzuki Hiroko   Matsumoto Shiro   Ito Midori   Maruyama Noriaki   Okada Kazuyoshi   Soma Masayoshi  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 3, 2013-02 ,pp. : 259-267

Informa Healthcare

Access to resources Recommend Favorite